Vaccine Trial Design Overhaul For HIV, Malaria, Tuberculosis Is FDA/WHO Project Goal
This article was originally published in Pharmaceutical Approvals Monthly
FDA grant will launch a collaborative agreement between the agency and the World Health Organization to create adaptive trial designs and explore new ways of tracking adverse event data.
You may also be interested in...
Pfizer and Moderna execs note they have sufficient resources with their partners to meet their vaccine production commitments. J&J, which has a manufacturing arrangement with Sanofi, is ready to ship four million doses of its vaccine upon receiving authorization from FDA.
Pfizer and Genentech execs describe steps they’ve taken to increase diversity in clinical trials from moving trial sites into new neighborhoods to modifying protocols and holding others accountable for diversity.
From biomarkers to treatment effect size, agency officials respond to some of more than a hundred questions that poured in during a webinar on development of drugs to treat the liver disease.